We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
CytoDyn (CYDY) is a biotech firm developing antibodies to combat serious medical conditions, such as HIV and cancer. The company is focused on exploring whether the antibody drug Leronlimab can contribute to the development of an HIV cure. CytoDyn was incorporated in 2002 and is based in Vancouver, Washington USA.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$1.25 - US$7.4 |
|---|---|
| 50-day moving average | US$1.7262 |
| 200-day moving average | US$2.021 |
| Target price | US$4 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$-0.255 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Historical closes compared with the last close of $1.5
| 1 week (2021-10-15) | 5.63% |
|---|---|
| 1 month (2021-09-22) | -39.02% |
| 3 months (2021-07-22) | -16.67% |
| 6 months (2021-04-22) | -54.27% |
| 1 year (2020-10-22) | -44.03% |
|---|---|
| 2 years (2019-10-22) | 376.19% |
| 3 years (2018-10-22) | 188.46% |
| 5 years (2016-10-21) | 127.27% |
| Revenue TTM | US$41,000 |
|---|---|
| Gross profit TTM | US$0 |
| Return on assets TTM | -57.11% |
| Return on equity TTM | 0% |
| Profit margin | 0% |
| Book value | 0.005 |
| Market capitalisation | US$937.5 million |
TTM: trailing 12 months
We're not expecting CytoDyn to pay a dividend over the next 12 months.
Over the last 12 months, CytoDyn's shares have ranged in value from as little as US$1.25 up to US$7.4. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (OTCQB average) beta is 1, while CytoDyn's is -0.8159. This would suggest that CytoDyn's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, CytoDyn has bucked the trend.
CytoDyn Inc. operates as a late-stage biotechnology company. The company focuses on developing treatments for multiple therapeutic indications based on leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. Its Leronlimab is in a class of therapeutic monoclonal antibodies designed to address unmet medical needs in the areas of human immunodeficiency virus (HIV), cancer, immunology, and novel coronavirus disease (COVID-19). The company has completed a Phase 2b pivotal trial using leronlimab in combination with antiretroviral therapies in HIV-infected treatment-experienced patients, as well as completed a Phase 2b/3 investigative trial with leronlimab as a once-weekly monotherapy for HIV-infected patients. It is also conducting a Phase 1b/2 clinical trial with leronlimab in metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Shares in the wealth management giant have been largely stable in the last 6 months.
Everything we know about the Judo Capital Holdings IPO, plus information on how to buy in.
Everything we know about the Alloggio Group IPO, plus information on how to buy in.
Everything we know about the Larvotto Resources IPO, plus information on how to buy in.
Everything we know about the Vulcan Steel IPO, plus information on how to buy in.
Everything we know about the Artrya IPO, plus information on how to buy in.
Everything we know about the 8 Au IPO, plus information on how to buy in.
Everything we know about the Radiopharm Theranostics IPO, plus information on how to buy in.
The online retailer’s shares have lost more than half their value in the last 12 months.
